An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients With Refractory Solid Tumors

Next Previous
Trial Profile

An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients With Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs AZD 2461 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 05 Jun 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top